Effects of progesterone withdrawal on uterine secretion of prostaglandin F2 alpha in response to oxytocin in ewes.
Two experiments were conducted to determine if withdrawal of progesterone during the luteal phase of the oestrous cycle affected the ability of the ovine uterus to secrete prostaglandin F2 alpha (PGF2 alpha) in response to oxytocin. In Experiment 1, 18 ewes were ovariectomized on Day 9 and Day 12 after oestrus. Ewes were subdivided into three treatment groups (n = 6 per group): Group-1 ewes underwent sham surgery; Group-2 ewes received oestradiol (OVX + O); and Group-3 ewes received oestradiol + progesterone (OVX + O,P). Oxytocin was administered to each ewe on Days 10, 13 and 15 after oestrus. Concentrations of 13, 14-dihydro-15-keto-PGF2 alpha (PGFM) were determined in samples of jugular venous blood for 2 h after oxytocin challenge. The magnitude of the PGFM response 24 h after ovariectomy was greater (P < 0.1) in ewes from which progesterone had been withdrawn (OVX + O) than in ewes in which progesterone was maintained (intact controls and OVX + O,P). Therefore, progesterone appears to exert an inhibitory effect on uterine secretory responsiveness to oxytocin which is removed by progesterone withdrawal. In Experiment 2, ewes were ovariectomized on Day 11 and assigned to 1 of 4 treatment groups (n = 6 per group): Group 1, no steroid replacement (OVX); Group 2, oestradiol replacement (OVX + O); Group 3, progesterone replacement (OVX + P); or Group 4, progesterone + oestradiol replacement (OVX + O,P). Ewes received oxytocin on Day 12 and Day 15. On Day 12, uterine secretory responsiveness to oxytocin was greatest in ewes in the OVX + O group (P < 0.1). Responsiveness was low in ewes in the OVX group, as it was in ewes in both groups that received progesterone replacement. Therefore, the increase in uterine secretory responsiveness to oxytocin following progesterone withdrawal is dependent on oestradiol replacement.
Kaminski
M A
MA
Department of Animal Sciences, University of Kentucky, Lexington 40546-0215, USA.
Hayes
S H
SH
Silvia
W J
WJ
D000818:Animals; D015237:Dinoprost / Q000378:metabolism*; D004958:Estradiol / Q000008:administration & dosage / Q000494:pharmacology; D004971:Estrus / Q000502:physiology; D005260:Female; D008183:Luteal Phase / Q000502:physiology; D010052:Ovariectomy; D010121:Oxytocin / Q000008:administration & dosage / Q000494:pharmacology*; D011374:Progesterone / Q000008:administration & dosage* / Q000494:pharmacology; D012756:Sheep / Q000502:physiology*; D013997:Time Factors; D014599:Uterus / Q000187:drug effects / Q000378:metabolism*
D011374:Progesterone; D004958:Estradiol; D010121:Oxytocin; D015237:Dinoprost